ENA 2022 Poster 343

HX301, a Novel CSF1Ri, Suppresses TAM and Enhances Tumor Immunity, Leading to Transit Tumor Response in Triple Negative Breast Cancer Syngeneic EMT-6 Model

Annie An, Mingfa Zang, Steven Xiong, Hang Ke, Tao Yang, Cen Chen, Lei Zhang, Faming Zhang, Henry Li

CSF1R is a receptor tyrosine kinase (RTK) responsible for the growth, survival and polarization (toward M2) of macrophages, thus implicated in pathogenesis of immunological disorders, including cancers.

High CSF1R expression is reported to be correlated to poorer prognosis of some malignances. CSF1R inhibitors (CSF1Ri), both TKIs or antibodies, have been proposed as potential cancer treatment strategy, although yet to be proven in the clinics.

Download this Poster to Discover:

• The preclinical in vitro and in vivo studies for HX301, a novel CSF1Ri

Download the Poster Now!